Paper7524641
Heat-stable antigen (CD24) as ligand for mouse P-selectin.
Sammar M and 6 others. Int Immunol, 1994. Cited by 107 papers, by iCite.
Cite this record
ConductScience Library. Heat-stable antigen (CD24) as ligand for mouse P-selectin. Papers, record 7524641. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/7524641
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics21
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antigens, CD | Major topic |
| Membrane Glycoproteins | Major topic |
| Platelet Membrane Glycoproteins | Major topic |
| Animals | |
| Binding Sites | |
| CD24 Antigen | |
| Cell Adhesion Molecules | |
| E-Selectin | |
| Endothelium | |
| Enzyme-Linked Immunosorbent Assay | |
| Immunoglobulin G | |
| Ligands | |
| Mice | |
| Mice, Inbred BALB C | |
| Mice, Inbred DBA | |
| Microspheres | |
| Neuraminidase | |
| P-Selectin | |
| Sialyltransferases | |
| Tumor Cells, Cultured | |
| beta-D-Galactoside alpha 2-6-Sialyltransferase |
Source PubMed
Cited by32
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 107 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41090358 | RCC2 and CD24 cooperate to modulate prostate cancer progression through vimentin ubiquitination and β-catenin activation. | J Clin Invest | 2025 | https://conductscience.org/library/papers/41090358 | PubMed |
| 40112946 | CD24 is required for sustained transparency of the adult lens. | Exp Eye Res | 2025 | https://conductscience.org/library/papers/40112946 | PubMed |
| 38655691 | Contribution of VEGF-B-Induced Endocardial Endothelial Cell Lineage in Physiological Versus Pathological Cardiac Hypertrophy. | Circ Res | 2024 | https://conductscience.org/library/papers/38655691 | PubMed |
| 38137380 | Targeting CD24 in Cancer Immunotherapy. | Biomedicines | 2023 | https://conductscience.org/library/papers/38137380 | PubMed |
| 37815040 | CellNeighborEX: deciphering neighbor-dependent gene expression from spatial transcriptomics data. | Mol Syst Biol | 2023 | https://conductscience.org/library/papers/37815040 | PubMed |
| 37228622 | CD24-Siglec interactions in inflammatory diseases. | Front Immunol | 2023 | https://conductscience.org/library/papers/37228622 | PubMed |
| 36969215 | Dendritic cell expression of CD24 contributes to optimal priming of T lymphocytes in lymph nodes. | Front Immunol | 2023 | https://conductscience.org/library/papers/36969215 | PubMed |
| 36425299 | CD24 as a Potential Therapeutic Target in Patients with B-Cell Leukemia and Lymphoma: Current Insights. | Onco Targets Ther | 2022 | https://conductscience.org/library/papers/36425299 | PubMed |
| 30414924 | Fluorometric Quantification of Single-Cell Velocities to Investigate Cancer Metastasis. | Cell Syst | 2018 | https://conductscience.org/library/papers/30414924 | PubMed |
| 28840297 | Therapeutic antibodies against cancer stem cells: a promising approach. | Cancer Immunol Immunother | 2017 | https://conductscience.org/library/papers/28840297 | PubMed |
| 28012129 | Expression of CD24 and Siglec-10 in first trimester placenta: implications for immune tolerance at the fetal-maternal interface. | Histochem Cell Biol | 2017 | https://conductscience.org/library/papers/28012129 | PubMed |
| 27738793 | Prognostic Significance of CD24 in Clear Cell Renal Cell Carcinoma. | Pathol Oncol Res | 2017 | https://conductscience.org/library/papers/27738793 | PubMed |
| 27203385 | Membranous CD24 drives the epithelial phenotype of pancreatic cancer. | Oncotarget | 2016 | https://conductscience.org/library/papers/27203385 | PubMed |
| 26578846 | Membranous CD24 expression as detected by the monoclonal antibody SWA11 is a prognostic marker in non-small cell lung cancer patients. | BMC Clin Pathol | 2015 | https://conductscience.org/library/papers/26578846 | PubMed |
| 26059947 | Dynamic regulation of CD24 expression and release of CD24-containing microvesicles in immature B cells in response to CD24 engagement. | Immunology | 2015 | https://conductscience.org/library/papers/26059947 | PubMed |
| 25666875 | CD24: from a Hematopoietic Differentiation Antigen to a Genetic Risk Factor for Multiple Autoimmune Diseases. | Clin Rev Allergy Immunol | 2016 | https://conductscience.org/library/papers/25666875 | PubMed |
| 25503963 | Clinicopathological and prognostic significance of CD24 overexpression in patients with gastric cancer: a meta-analysis. | PLoS One | 2014 | https://conductscience.org/library/papers/25503963 | PubMed |
| 21984372 | CD24 promotes tumor cell invasion by suppressing tissue factor pathway inhibitor-2 (TFPI-2) in a c-Src-dependent fashion. | Clin Exp Metastasis | 2012 | https://conductscience.org/library/papers/21984372 | PubMed |
| 20154703 | CD24: from A to Z. | Cell Mol Immunol | 2010 | https://conductscience.org/library/papers/20154703 | PubMed |
| 18504038 | Cell-surface nucleolin is a signal transducing P-selectin binding protein for human colon carcinoma cells. | Exp Cell Res | 2008 | https://conductscience.org/library/papers/18504038 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/7524641
GET https://conductscience.org/api/papers/v1/7524641/cited_by?page=2